Evaluating the clinical utility of the patient‐identified most bothersome symptom measure from PROMISE‐2 for research in migraine prevention

OBJECTIVE: To assess the utility of the novel patient‐identified (PI) most bothersome symptom (MBS) measure from PROMISE‐2, a phase 3 trial of eptinezumab for the preventive treatment of chronic migraine. BACKGROUND: Relief of bothersome migraine symptoms can influence satisfaction with treatment an...

Descripción completa

Detalles Bibliográficos
Autores principales: Lipton, Richard B., Goadsby, Peter J., Dodick, David W., McGinley, James S., Houts, Carrie R., Wirth, R. J., Kymes, Steve, Ettrup, Anders, Østerberg, Ole, Cady, Roger, Ashina, Messoud, Buse, Dawn C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Submissions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325355/
https://www.ncbi.nlm.nih.gov/pubmed/35466430
http://dx.doi.org/10.1111/head.14295

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325355/
https://www.ncbi.nlm.nih.gov/pubmed/35466430
http://dx.doi.org/10.1111/head.14295

Ejemplares similares